Menopause is the point one year after your last period. The years of change before it, perimenopause, are usually when hot flashes, night sweats, and broken sleep are worst. Of the treatments tested for hot flashes and night sweats, hormone therapy works best: it cuts them by about 75% and also protects bone. Its risks are specific, and in plain numbers they are smaller than the fear the first large trial set off. The main ones: a small rise in breast cancer with longer combined use, and blood clots that run higher with tablets than with a skin patch.
For women who cannot take hormones or prefer not to, cognitive behavioral therapy, the neurokinin-blocking drugs, and low-dose antidepressants all help. Local vaginal estrogen relieves dryness at very low risk. Strength training protects the bone that thins fastest in these years. Most botanicals sold for menopause, black cohosh and red clover among them, come out level with placebo. Chinese medicine reads the whole transition as the body's cooling reserve running low, so once too little cooling is left, heat rises unchecked.
Practice Ranking
Every practice we track for Menopause and Hot Flashes: What the Transition Is and What Helps, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
3 practices · 1 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Resistance Training: What It Does, the Low Dose That Works, and How to Start Heavy resistance and impact training builds bone through the transition when loss is fastest; exercise has not been shown to cut hot flashes specifically. | Moderate | Self-Directed | Free to $$ | Moderate to Hard | Weeks to Months | |
| 2 | CBT-I: What It Does for Long-Term Insomnia, Why It Beats Pills, and How to Do It Sleep-restriction and stimulus-control therapy moved most women out of the insomnia range for menopausal sleep disruption. | Moderate | Self-Directed | Free to $$ | Hard | Weeks | |
| 3 | Cognitive Behavioral Therapy: What It Treats, How Strong the Evidence Is, and How to Start CBT reduces how much hot flashes bother you, without hormones. | Moderate | Self-Directed | Free to $$ | Moderate to Hard | Weeks | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Menopause is the point one year after your last period, for most women around age 51. It is identified only in retrospect. The years before it, perimenopause, are usually when symptoms run worst, and they often ease afterward.
Through perimenopause the ovaries lose function unevenly, so estrogen does not decline steadily. It swings up and down, sometimes higher than before. That instability is why hot flashes, night sweats, mood changes, and broken sleep in these years feel erratic and intense.
Hot flashes and night sweats, the symptoms most women feel, begin in the brain. As estrogen falls, the part of the hypothalamus that sets body temperature narrows its comfortable range. A small rise in core temperature, one you would once have ignored, now triggers the full flush and sweat that sheds the heat. A cluster of neurons signaling with neurokinin B drives that flush, which is why the newest non-hormonal drugs block that exact signal.
For many women the frequent flashes last for years, and they run longest when they begin early in the transition. Surgical menopause (both ovaries removed) and early menopause (from ovarian insufficiency, chemotherapy, or radiotherapy) both drop estrogen within hours or months. Symptoms hit fast, and the longer lifetime at low estrogen changes long-term bone and heart risk. When menopause comes early or abruptly, doctors usually advise starting hormone therapy and continuing it at least until the average age of natural menopause.
Two common conditions imitate menopause closely and improve with neither hormones nor herbs: thyroid disease and iron deficiency. Both cause heat intolerance, sweating, palpitations, disturbed sleep, and fatigue, and both are cheap to check with a blood test you can arrange yourself or through a doctor. Rule them out first, before months are spent treating the wrong thing.
Any bleeding a year or more after your last period needs a doctor.
What Helps
Once those look-alikes are ruled out, start with what you can do yourself. A cooler bedroom and lighter, breathable bedding work directly against night sweats, because falling asleep depends on core temperature dropping. When broken sleep becomes a problem of its own and outlasts the flashes, cognitive behavioral therapy for insomnia, CBT-I, has the strongest evidence. It worked in women still having hot flashes. Bone thins fastest in a short window around the final period. Heavy resistance and impact training is the lever you control directly: a supervised program builds bone in postmenopausal women whose bone is thinning.
Hormone therapy is the strongest lever for the flashes and night sweats, and it also protects bone. It cuts them by about 75% against a dummy pill, more than any other treatment tested (MacLennan, Cochrane 2004). For most women with troublesome symptoms and no reason to avoid it, it is the first drug choice. If you still have a uterus it is given with a progestogen to protect the uterine lining. After a hysterectomy the estrogen is given alone, which carries less risk. Its risks are specific, and in plain numbers they are smaller than the fear that followed the first large trial. Three points shape the decision:
- The breast cancer risk is tied mainly to the combined estrogen-plus-progestogen form, and grows with years of use; estrogen alone raises it much less.
- Blood clots and stroke run higher when estrogen is swallowed as a tablet and passes through the liver first; estrogen absorbed through a skin patch does not raise them.
- The balance is more favorable for a woman who begins near menopause, before 60 or within 10 years of her last period. It was less favorable for the women in their sixties, whom the first alarm was drawn from.
Over 18 years, hormone therapy neither shortened nor lengthened life overall, so the choice rests on symptoms and these specific risks. The menopausal hormone therapy guide lays the numbers out in full.
For women who cannot take hormones or prefer not to, several non-hormonal treatments have trial support. Each is weaker than estrogen for flashes, and each is worth considering:
- the neurokinin-blocking drugs fezolinetant and elinzanetant, the newest and strongest, cutting flashes by about two to three more per day than placebo (Lederman, Lancet 2023; Pinkerton, JAMA 2024).
- low-dose SSRIs and SNRIs, gabapentin, and clonidine, each easing flashes by a smaller amount.
- a short course of cognitive behavioral therapy, which lowers how much the flashes bother you without changing how often they come.
That CBT course worked even for women having flashes after breast cancer treatment.
Local vaginal estrogen (a cream, tablet, or ring) treats vaginal dryness, painful sex, and recurrent urinary symptoms, and it carries low risk of its own. Very little reaches the bloodstream, so users do not show the clot or cancer signals systemic therapy can carry. It stays open to many women who cannot take the systemic form.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Menopause And Vasomotor
Hormone therapy cut hot flashes about 75%, roughly 18 fewer a week
Hormone therapy is the most effective treatment measured for hot flashes and night sweats, cutting them about 75%, roughly 18 fewer a week. Much of the early relief in any arm is the placebo effect, since the placebo groups improved about 58%.
75% fewer hot flashes than placebo (95% CI 64.3 to 82.3), about 18 fewer per week. Severity odds ratio 0.13 (0.07 to 0.23). Measured in: 24 randomized trials, 3,329 participants, oral estrogen and combined estrogen-progestogen. The placebo arms of the same trials improved by 57.7%, so most of what a woman notices in the first weeks of any treatment is not the drug. The review is from 2004 and predates the low-dose and transdermal preparations now most often prescribed.
The study · 1
MacLennan et al., oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes · Cochrane Database Syst Rev 2004
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Placebo alone cut hot flashes about 58% in the same trials
In the pooled hormone trials, women given a placebo cut their hot flashes about 58%, and a third were clearly better by week 8. That large response is why a before-and-after with no comparison cannot show that a remedy worked.
Placebo arms in the pooled hormone trials cut hot flashes by 57.7% (95% CI 45.1 to 67.7). In a pooled analysis of placebo-treated women, 33% were significantly improved by week 8, and 77% of those were still improved at week 11, three weeks after treatment stopped. Measured in: 3,329 participants across 24 hormone trials; 247 placebo and 297 actively treated women in the pooled placebo analysis. A placebo arm captures regression to the mean, the natural waxing and waning of symptoms, and the effect of daily symptom diaries, not only expectation. It is why an uncontrolled trial or a personal before-and-after cannot tell you whether something worked.
The studies · 2
MacLennan et al., oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes · Cochrane Database Syst Rev 2004
Freeman et al., placebo improvement in pharmacologic treatment of menopausal hot flashes: time course, duration, and predictors · Psychosom Med 2015
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Fezolinetant and elinzanetant cut hot flashes about 2 to 3 more a day than placebo
The neurokinin-blocking drugs fezolinetant and elinzanetant cut hot flashes by about 2 to 3 more a day than a dummy pill. They are the first non-hormonal drugs aimed at the brain signal that drives flashes.
In its phase 3 trial (SKYLIGHT 1), fezolinetant 45 mg reduced daily hot flashes by about 2.55 in frequency and 2.39 in severity more than placebo by week 12. In its phase 3 trials (OASIS 1 and 2), elinzanetant 120 mg reduced them by about 3.2 by week 12. Together the two drugs enrolled about 1,300 women. Measured in: About 1,300 women aged 40 to 65 with moderate to severe vasomotor symptoms across the SKYLIGHT 1 and OASIS phase 3 trials. Both drugs were tested against placebo, not against hormone therapy, so nothing here establishes which works better. Fezolinetant carries a liver-monitoring schedule, at baseline and months one, two, three, six, and nine.
The studies · 2
CBT lowered how much hot flashes bother you about 2 points on a 10-point scale
A short course of CBT lowered how much hot flashes and night sweats bother you by about 2 points on a 10-point scale, holding for months. It changes the distress more than the number of flashes, and it worked after breast cancer treatment.
Group CBT and a self-help CBT booklet both beat usual care on the hot flash and night sweat problem rating at 6 weeks, adjusted mean differences 2.12 and 2.08 on a 10-point scale, holding at 26 weeks. After breast cancer treatment, group CBT gave a mean difference of 1.67 (95% CI 0.91 to 2.43) at 9 weeks. Measured in: 140 women with problematic hot flashes and night sweats (MENOS 2); 96 women with symptoms after breast cancer treatment (MENOS 1). What moves is how much the flashes bother you, not how many you have; measured frequency changed much less than the problem rating. Neither trial could blind participants, and both were run by the group that developed the intervention.
The studies · 2
Mann et al., cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial · Lancet Oncol 2012
Acupuncture worked no better than sham needling for hot flashes
Across 8 trials and 414 women, acupuncture was no better than sham needling for hot flashes. It did beat no-treatment comparisons, the gap that marks a large placebo-type response.
In a Cochrane review, the sham-controlled comparison pooled 8 trials and 414 women and found no difference from sham needling in hot flash frequency, MD -1.13 per day (95% CI -2.55 to 0.29). Against no treatment, in 3 trials and 463 women, acupuncture did better. The largest single trial, 327 women, found no difference from sham at the end of treatment, MD 0.33 (-1.87 to 2.52). Measured in: 8 trials and 414 women in the sham-controlled comparison, 3 trials and 463 in the no-treatment comparison; 327 women aged 40 and over in the single largest trial. Against no treatment or a waiting list, acupuncture did better in the same review. That gap between the sham-controlled and untreated comparisons is the signature of a large non-specific response, and it is why a hot-flash trial without a sham arm cannot answer the question. Adverse event reporting was sparse. The sham-controlled estimate rests on 8 trials and 414 women and the no-treatment estimate on only 3 trials and 463, so both carry less weight than the review's headline count suggests.
The studies · 2
Dodin et al., acupuncture for menopausal hot flushes · Cochrane Database Syst Rev 2013
Ee et al., acupuncture for menopausal hot flashes: a randomized trial · Ann Intern Med 2016
Fixed Chinese herbal formulas matched placebo for hot flashes
Across 22 trials and 2,902 women, fixed Chinese herbal formulas matched placebo for hot flashes. Nearly all gave one formula to everyone, which is not how the medicine is practiced, where the formula is matched to the person.
22 randomized trials and 2,902 women: no difference from placebo in hot flashes per day, MD 0.00 (95% CI -0.88 to 0.89). Measured in: 2,902 women, most trials conducted in China. Twenty of the twenty-two trials gave one fixed formula to everyone enrolled, which is not how the medicine is prescribed, and no trial at all tested the pattern-matched, individualized prescribing the tradition actually claims works. Adverse events were incompletely reported; those recorded were mild diarrhea, breast tenderness, gastric discomfort and an unpleasant taste.
The study · 1
Zhu et al., Chinese herbal medicine for menopausal symptoms · Cochrane Database Syst Rev 2016
Black cohosh matched placebo for hot flashes
Across 16 trials and 2,027 women, black cohosh was no different from placebo for hot flash frequency. Trials used standardized extracts, while retail products vary in species, plant part, and dose.
16 randomized trials and 2,027 women: no difference from placebo in hot flash frequency, MD 0.07 per day (95% CI -0.43 to 0.56). Measured in: 2,027 perimenopausal and postmenopausal women. The reviewers judged safety reporting too poor to draw a conclusion from, which is a separate matter from the efficacy result. Trials used standardized extracts, while retail products vary in species, plant part, extraction and dose.
The study · 1
Leach and Moore, black cohosh (Cimicifuga spp.) for menopausal symptoms · Cochrane Database Syst Rev 2012
Exercise did not reduce hot flashes specifically
Exercise did not reduce hot flashes specifically across 5 trials and 733 women. The same women still get exercise's benefits to bone, heart, sleep, and mood, which this review did not measure.
Five trials, 733 women: no difference between exercise and no active treatment in the frequency or intensity of vasomotor symptoms, SMD -0.10. Measured in: 733 perimenopausal and postmenopausal women. This measured hot flashes and nothing else. The same women still get the bone, cardiovascular, sleep and mood effects of exercise, none of which this review looked at. Trials were small and the exercise programs differed enough that pooling them is rough.
The study · 1
Daley et al., exercise for vasomotor menopausal symptoms · Cochrane Database Syst Rev 2014
Frequent hot flashes lasted a median of 7.4 years, about 4.5 of them after the final period
Frequent hot flashes lasted a median of 7.4 years, about 4.5 of them after the final period, and longer for women whose flashes began early. This describes women with frequent symptoms, not every woman.
Median total duration of frequent vasomotor symptoms was 7.4 years, with a median 4.5 years continuing after the final period. Women whose symptoms started while still premenopausal or in early perimenopause had a median duration above 11.8 years; those whose symptoms started after the final period, 3.4 years. Measured in: 1,449 women with frequent vasomotor symptoms in the Study of Women's Health Across the Nation, followed up to 17 years. What could explain it instead: Symptom onset was self-reported at annual visits, so recall sets the start date, and women with the worst symptoms are the most likely to have started hormone therapy and left the untreated analysis, which would shorten the observed duration, not lengthen it.. This describes women with frequent symptoms, so it is not the average experience of every woman. Duration varied by ethnicity, with a median of 10.1 years in African American participants, and by education and baseline stress.
The study · 1
Avis et al., duration of menopausal vasomotor symptoms over the menopause transition · JAMA Intern Med 2015
Red clover for hot flashes came out mixed and small, with no effect in the largest review
Red clover isoflavones came out mixed and small: the largest review found no difference from placebo, a later one a small effect. Set against a placebo response that itself halves flashes, any signal is minor.
Cochrane pooled the red clover extract trials and found no difference from placebo, MD -0.93 hot flashes per day (95% CI -1.95 to 0.10). A 2026 review of 9 trials reported a small effect, SMD -0.446 (-0.807 to -0.084). Measured in: 4,364 participants across 43 phytestrogen trials; 9 trials of women aged 40 to 65 in the later review. The two reviews disagree and overlap in the trials they include. The newer one reports a standardized effect size, not flashes per day, so it cannot be read as a count, and a standardized difference of 0.45 against a placebo arm that itself falls by half is a small signal.
The studies · 2
Lethaby et al., phytoestrogens for menopausal vasomotor symptoms · Cochrane Database Syst Rev 2013
Jiang and Wu, the effectiveness of red clover on hot-flash in menopausal women: a GRADE-assessed systematic review and meta-analysis · Eur J Obstet Gynecol Reprod Biol 2026
Longevity And Mortality
Hormone therapy did not change deaths over 18 years (27.1% against 27.6%)
Over 18 years, 27.1% of women given hormone therapy died against 27.6% given placebo, no meaningful difference. It neither shortens nor lengthens life overall, so the decision rests on symptoms and specific risks.
27.1% of women assigned hormone therapy died against 27.6% assigned placebo, HR 0.99 (95% CI 0.94 to 1.03). Cardiovascular mortality HR 1.00, cancer mortality HR 1.03. During the treatment years the ratio of hazard ratios for ages 50 to 59 against 70 to 79 was 0.61 (0.43 to 0.87). Measured in: 27,347 women aged 50 to 79 at randomization, 18 years of cumulative follow-up, 7,489 deaths. A null on mortality is not a null on every outcome. The same trials found differences in stroke, clot and breast cancer, and a treatment can move those without moving the death rate. The age comparison is a subgroup finding within a trial not designed to test it.
The study · 1
Genitourinary
Local vaginal estrogen relieved dryness and painful sex (odds ratios of 4 to 13)
Across 30 trials and 6,235 women, estrogen used in the vagina relieved dryness and painful sex far better than placebo, with odds ratios from about 4 to 13 depending on the preparation, and creams, tablets, and rings worked about equally.
Across 30 randomized trials and 6,235 women, intravaginal estrogen improved symptoms against placebo, with odds ratios between 4.10 and 12.67 depending on preparation. Creams, tablets and rings did not differ from each other in effect. Measured in: 6,235 postmenopausal women with vaginal atrophy. Most trials ran only about 12 weeks, so long-term endometrial safety rests on observational data, not on these trials. The outcome measures for dryness and discomfort varied enough that pooling them is approximate.
The study · 1
Lethaby et al., local oestrogen for vaginal atrophy in postmenopausal women · Cochrane Database Syst Rev 2016
Bone Density
Hormone therapy cut total fractures about a quarter (hazard ratio 0.76)
Hormone therapy cut total fractures about a quarter (hazard ratio 0.76) and raised hip bone density. The protection holds, though bone alone is not a reason to start hormones late in life.
Total fractures HR 0.76 (95% CI 0.69 to 0.83) and 5 fewer hip fractures per 10,000 women per year. Total hip bone density rose 3.7% over three years against 0.14% on placebo. Measured in: 16,608 postmenopausal women aged 50 to 79. The fracture reduction held across women at every level of baseline fracture risk, and it sat inside a trial whose overall balance in that age group was unfavorable. The authors' own conclusion was that there was no net benefit. Bone protection alone is not a reason to start hormone therapy at 70.
The study · 1
Spine bone density fell about 10.6% over the decade around menopause, most of it in a short window
Spine bone density fell about 10.6% over the decade around menopause, and most of that, about 7%, happened in the short window from a year before the final period to two years after. Bone density is a risk marker, not a fracture.
Cumulative 10-year lumbar spine bone density loss was 10.6%, of which 7.38% happened during the transmenopause, the window from one year before the final period to two years after. Femoral neck loss was 9.1%, with 5.8% in that same window. Measured in: 862 women followed through the decade around their final menstrual period: 242 African American, 384 white, 117 Chinese, 119 Japanese. What could explain it instead: Ordinary age-related bone loss runs at the same time as the menopause-related loss, and an observational cohort cannot fully separate the two, so some of the attributed loss belongs to aging.. Rates differed by body size and ancestry: higher BMI and African American heritage went with slower loss, Chinese and Japanese ancestry with faster. Bone density is a risk marker, not a fracture.
The study · 1
Greendale et al., bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN) · J Bone Miner Res 2012
Heavy resistance and impact training raised spine bone density 2.9% while untrained women lost 1.2%
A supervised program of heavy resistance and impact training, 30 minutes twice a week, raised spine bone density 2.9% while an untrained group lost 1.2%. The loads were heavy and needed coaching.
Lumbar spine bone density rose 2.9% in the training group against a 1.2% loss in controls (P<0.001); femoral neck 0.3% against a 1.9% loss (P=0.004). The program was 30 minutes twice a week for 8 months. Measured in: 101 postmenopausal women with osteopenia or osteoporosis, mean age around 65. One site, supervised throughout, and the comparison was a low-intensity home program, not nothing. The loads were heavy and the technique needs coaching, so this is not a description of what unsupervised gym training does.
The study · 1
Watson et al., high-intensity resistance and impact training improves bone mineral density and physical function in postmenopausal women with osteopenia and osteoporosis: the LIFTMOR randomized controlled trial · J Bone Miner Res 2018
Measurement And Diagnosis
About 9% of women who bleed after menopause had endometrial cancer
About 9% of women who bleed after menopause turn out to have endometrial cancer, and 91% of women with that cancer had reported bleeding. Most bleeding is not cancer, which is exactly why every episode is checked.
Across 129 studies, 9% of women with postmenopausal bleeding turned out to have endometrial cancer (95% CI 8 to 11), and 91% of women with endometrial cancer had reported bleeding (87 to 93). Measured in: 34,432 women with postmenopausal bleeding; 6,358 women with endometrial cancer. Most women who bleed do not have cancer. The 9% is the reason every episode is investigated, not watched, and the 91% is why bleeding is the symptom that finds the disease early. Prevalence varied with hormone therapy use, which causes benign bleeding of its own.
The study · 1
Clarke et al., association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis · JAMA Intern Med 2018
Heart And Vascular
Started within 6 years of menopause, estrogen slowed artery-wall thickening (0.0044 against 0.0078 mm a year)
Started within 6 years of menopause, estrogen slowed the thickening of an artery wall (0.0044 against 0.0078 mm a year); started 10 or more years later it did not. This is a marker, not heart attacks measured directly.
In women less than 6 years past menopause, carotid intima-media thickness rose 0.0044 mm per year on oral estradiol against 0.0078 on placebo (P=0.008). In women 10 or more years past, 0.0100 against 0.0088 (P=0.29). Interaction P=0.007. Measured in: 643 healthy postmenopausal women, stratified by time since menopause. Carotid wall thickness is a surrogate. The trial was not powered for heart attacks or strokes and did not measure them as endpoints, so this shows a difference in a marker, not in events. Participants were healthy volunteers without cardiovascular disease.
The study · 1
Hodis et al., vascular effects of early versus late postmenopausal treatment with estradiol (ELITE) · N Engl J Med 2016
Sleep
CBT for insomnia moved 84% of women out of the insomnia range, against 43% of controls
CBT for insomnia cut insomnia severity about 5 points more than the comparison group, and by 24 weeks 84% of the CBT group were out of the insomnia range against 43%. The flashes themselves barely changed; the sleep around them improved.
Telephone-delivered CBT for insomnia dropped the Insomnia Severity Index by 9.9 points against 4.7 in the control arm, a difference of 5.2 points at 8 weeks. By 24 weeks, 84% of the CBT group scored in the no-insomnia range against 43% of controls. Measured in: 106 perimenopausal and postmenopausal women, mean age 54 to 55, with insomnia and hot flashes. Small, one research network, and the control arm was menopause education, not an equally intensive sleep program, so some of the gap is attention. Hot flash frequency itself barely changed; what improved was the sleep around them.
The study · 1
McCurry et al., telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: a MsFLASH randomized clinical trial · JAMA Intern Med 2016
What comes out level with placebo
Hot flashes come and go on their own and respond strongly to attention and expectation, so almost anything taken during a bad stretch feels like it worked. In the botanical trials the placebo arms alone cut flashes by about 58% (Leach & Moore, Cochrane 2012; Lethaby, Cochrane 2013). A before-and-after with no comparison group cannot tell you whether a remedy worked. Black cohosh, the botanical most often sold for menopause, also carries more than 50 published reports of liver injury, a separate matter from whether it eases flashes.
Measured against placebo, the popular options came out level:
- black cohosh matched placebo across 16 trials and 2,027 women.
- red clover was no better than placebo in the largest review.
- fixed Chinese herbal formulas given identically to everyone in a trial come out level too.
- acupuncture beats no treatment but does no better than sham (fake) needling, the sign that most of the benefit is a placebo effect.
- exercise helps bone, heart, and mood, but did not reduce hot flashes specifically.
Go Deeper
- Menopausal hormone therapy: the full decision, with the benefits and the plain-number risks in detail.
- Perimenopause: the run-up, when symptoms are worst.
- Osteoporosis: the bone loss that concentrates around the final period.
- Insomnia: the CBT-I that treats broken sleep once it outlasts the flashes.
- Resistance training: the strength work that builds bone back.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine reads the transition as the Kidneys emptying with age. The cooling, moistening Yin depletes first, so the warmth it once balanced rises as empty heat, the heat of depletion. Which pattern you have points to what supports it. The tradition treats it by nourishing the depleted Yin. Trials of one fixed formula given to everyone come out level with placebo. That is not how the medicine is practiced, a practitioner matches the formula to the pattern after reading the pulse and tongue.
The central picture: hot flashes rising to the face and chest, night sweats that come in sleep and stop on waking, heat in the palms, soles, and center of the chest, dry mouth and eyes, vaginal dryness, weak low back and knees. Points toward nourishing Yin, the Liu Wei Di Huang and Zhi Bai Di Huang families, with Qing Hao Bie Jia Tang when the heat is worst in the small hours.
The same Yin depletion with the Shen now unsettled by it: waking at two or three, palpitations, free-floating anxiety, racing thoughts, vivid dreams. Tian Wang Bu Xin Dan is the classical answer.
Flashes and sweating together with cold feet, aversion to cold, low libido, and exhaustion. Common in the transition, and what Er Xian Tang was built for, warming Yang tonics paired with fire-draining herbs in the one prescription.
Sudden irritability, weeping, rib-side and breast distension, headaches, a bitter taste, tension that discharges as anger. The Xiao Yao San family, modified toward cooling once the stagnation has turned to heat.
Emotional lability, unprovoked weeping, yawning, restlessness, poor concentration, palpitations, a pale complexion. Gan Mai Da Zao Tang for the restless picture, Gui Pi Tang where the depletion of Blood leads.
Risks and Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Estrogen plus progestin added about 8 breast cancers per 10,000 women a year
Per 10,000 women per year: 7 more coronary events, 8 more strokes, 8 more pulmonary emboli, 8 more invasive breast cancers, against 6 fewer colorectal cancers and 5 fewer hip fractures. Hazard ratios 1.29 for coronary heart disease, 1.41 stroke, 2.13 pulmonary embolism, 1.26 breast cancer. Mean age at entry was 63 and most participants were more than a decade past their final period, which is not the woman who asks about hormone therapy for symptoms. One oral formulation was tested: conjugated equine estrogen with medroxyprogesterone acetate. The breast cancer hazard ratio's confidence interval touched 1.00.Rossouw et al., risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial
Estrogen alone did not raise breast cancer, and added about 12 strokes per 10,000 women a year
Over 6.8 years: 12 more strokes and 6 fewer hip fractures per 10,000 women per year, and no increase in coronary events (HR 0.91). Breast cancer HR 0.77 (0.59 to 1.01) during the trial and 0.79 (0.65 to 0.97) across 13 years of cumulative follow-up, a reduction, not an increase. This arm only describes women without a uterus. A woman with a uterus needs a progestogen to protect the endometrium, and the progestogen is where most of the breast cancer signal sits. The stroke increase appears in both arms and does not go away with age stratification.Anderson et al., effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trialManson et al., menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials
Five years of estrogen plus daily progestagen added about 1 breast cancer per 50 users
Five years of therapy started at age 50 adds roughly one breast cancer per 50 users of estrogen with daily progestagen, one per 70 with intermittent progestagen, and one per 200 with estrogen alone, counted across ages 50 to 69. Ten years is about twice that. Relative risk in current users of 5 to 14 years: 2.08 for estrogen-progestagen, 1.33 for estrogen alone. Individual participant data pooled from prospective observational studies, not from randomized trials, and the direction disagrees with the WHI estrogen-alone arm. Vaginal estrogens were the one preparation with no excess. Some excess risk persisted more than a decade after stopping.Collaborative Group on Hormonal Factors in Breast Cancer, type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence
Started at 50 to 59, estrogen alone ran about 26 fewer events per 10,000 women a year; started at 70 to 79, about 33 more
Stratified by age, estrogen alone at 50 to 59 ran 26 fewer events per 10,000 women per year, against 33 more at 70 to 79, over 13 years of cumulative follow-up. These are the 13-year cumulative figures. The intervention-phase numbers, gathered while women were actually taking the hormones, are different and the two are routinely quoted interchangeably. The age gradient is the finding that changed prescribing, and it is an observation within a randomized trial, not a randomized comparison of ages.Manson et al., menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials
Oral hormone therapy raised blood clots (odds ratio 1.58); the skin patch did not (0.93)
Oral hormone therapy was associated with venous thromboembolism, adjusted odds ratio 1.58 (95% CI 1.52 to 1.64); oral estrogen alone 1.40, oral combined preparations 1.73. Transdermal preparations showed no increase, 0.93 (0.87 to 1.01). Nested case-control drawn from prescribing records, so exposure is what was dispensed, not what was swallowed or worn. Route was not randomized, and no trial has randomized oral against transdermal with clot as the endpoint.Vinogradova et al., use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
Vaginal estrogen carried none of the systemic hormone risks (composite hazard ratio 0.68)
Among 45,663 postmenopausal women, users of vaginal estrogen had no higher risk of stroke, heart attack, pulmonary embolism, hip fracture, breast cancer, colorectal cancer or endometrial cancer than non-users. In women with an intact uterus the composite index favored users, adjusted HR 0.68 (95% CI 0.55 to 0.86). Observational, not randomized, so it cannot rule out a small effect. The finding describes the low-dose preparations in use during that study, not every product now sold, and women with a history of breast cancer were not the population studied.Crandall et al., breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study
More than 50 cases of liver injury reported with black cohosh products
More than 50 published cases of clinically apparent liver injury. Latency typically 2 to 12 weeks, range 1 to 48 weeks, hepatocellular pattern with jaundice, ranging from asymptomatic enzyme rises to acute liver failure needing transplant. LiverTox assigns likelihood category A. Causality is contested. Adulteration and misidentified species are documented alternative explanations, and the number of total users is unknown, so no rate can be calculated from these cases. Systematic causality assessment has downgraded many of the reports.LiverTox: clinical and research information on drug-induced liver injury, black cohosh chapterTeschke et al., herbal hepatotoxicity: suspected cases assessed for alternative causes
Starting or changing hormone therapy is a decision made with a prescriber
The risks above are specific and shift with your age, how you take the hormone, and whether you still have a uterus. Do not start or stop a prescribed hormone on your own, that conversation belongs with whoever prescribes it.
Salivary hormone tests do not guide a dose
Saliva hormone tests marketed to tailor a custom-compounded "bioidentical" prescription do not track a reliable dosing target. Compounded products face less regulatory oversight of dose and purity than the regulated, FDA-approved bioidentical hormones.
Menopause is a natural transition, and most of what it brings is manageable with the levers here. Take a history that needs weighing to a licensed practitioner.
When to See Someone
Most of the transition is not dangerous and needs no doctor. These are the signs that do. See a doctor about any of them, and urgently for the last one, if you have:
- Any bleeding twelve months or more past your last period, and any bleeding on hormone therapy outside an expected withdrawal bleed. About 9% of women who bleed after menopause turn out to have endometrial cancer, which is why every episode is checked, spotting included (Clarke, JAMA Internal Medicine 2018).
- Bleeding after sex, or new heavy, prolonged, or between-period bleeding during the years of irregular cycles.
- A new breast lump, a nipple change, or a change in the skin of the breast.
- New pelvic pain that is persistent, or that is new for you.
- New fatigue, palpitations at rest, or breathlessness. These point more at the thyroid or low iron than at menopause, and are worth a blood test.
- Persistent low mood, loss of interest, or thoughts of harming yourself.(seek urgent care)
The signs listed are the few that warrant a check. Any bleeding after menopause warrants prompt attention.
Common Questions
Is hormone therapy safe?
For most women with symptoms the benefits outweigh the risks, and the decision belongs with whoever prescribes it. The 2002 alarm came from a trial of women mostly in their sixties, long past their final period. In it, estrogen plus a progestogen added about 8 extra breast cancers, 8 strokes, and 8 lung clots per 10,000 women a year (Rossouw, JAMA 2002). For a woman who begins near menopause the picture is better. Five years of estrogen alone adds only about one breast cancer per 200 women (Collaborative Group, Lancet 2019). The hormone therapy guide walks through it.
How long do hot flashes usually last?
Longer than most expect. Among women with frequent flashes they lasted a median of 7.4 years, about 4.5 of them after the final period. They ran longer still, above 11 years, for women whose flashes started early in the transition (Avis, JAMA Internal Medicine 2015).
What helps the broken sleep?
When broken sleep outlasts the flashes, a course of CBT-I cut insomnia severity about 5 points more than the comparison group in women still having hot flashes. By 24 weeks 84% were out of the insomnia range, against 43% of controls (McCurry, JAMA Internal Medicine 2016).
Does anything protect my bones through the transition?
Yes. Bone loss concentrates around the final period, about a tenth of spine density over the surrounding decade (Greendale, JBMR 2012). Hormone therapy cuts total fractures about a quarter (Cauley, JAMA 2003). Heavy resistance and impact training builds it directly: a supervised program of 30 minutes twice a week raised spine bone density about 3%. An untrained group kept losing it (Watson, JBMR 2018).
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
How this connects
- Compared here
All 32 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.